CYTOMX THERAPEUTICS
CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
CYTOMX THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2008-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.cytomx.com
Total Employee:
51+
Status:
Active
Contact:
6503510353
Total Funding:
345.42 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics WordPress Google Universal Analytics Nginx Amazon IPv6 AJAX Libraries API
Similar Organizations
AquaBounty Technologies
AquaBounty Technologies is a biotechnology company that focuses on improving productivity in commercial aquaculture.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2005-03-30 | Ardais Corporation | Ardais Corporation acquired by CytomX Therapeutics | N/A |
Investors List
Wellington Management
Wellington Management investment in Series D - CytomX Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series D - CytomX Therapeutics
Deerfield
Deerfield investment in Series D - CytomX Therapeutics
Casdin Capital
Casdin Capital investment in Series D - CytomX Therapeutics
Tekla Capital Management
Tekla Capital Management investment in Series D - CytomX Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series D - CytomX Therapeutics
Venrock
Venrock investment in Series D - CytomX Therapeutics
Redmile Group
Redmile Group investment in Series D - CytomX Therapeutics
Canaan Partners
Canaan Partners investment in Series C - CytomX Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series C - CytomX Therapeutics
Key Employee Changes
Official Site Inspections
http://www.cytomx.com Semrush global rank: 40.86 K Semrush visits lastest month: 3.13 M
- Host name: 73.38.148.146.bc.googleusercontent.com
- IP address: 146.148.38.73
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "CytomX Therapeutics"
About - CytomX
Danielle Olander-Moghadassian joined CytomX in 2014, and currently serves as consulting chief human resources officer. She is accountable for optimizing talent, bringing organizational …See details»
CytomX Therapeutics - LinkedIn
CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage …See details»
Investor Relations | CytomX Therapeutics, Inc.
Mar 12, 2025 CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. CytomX is advancing potential first-in …See details»
CytomX Therapeutics - Crunchbase Company Profile & Funding
CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients …See details»
CytomX's Leadership Team Team - Team members and org chart
The leadership team at CytomX has a lot of experience in the pharmaceutical industry. The CEO has worked at CytomX Therapeutics Inc, and before that was a transactional partner at …See details»
CytomX Therapeutics Announces First Quarter 2025 Financial …
16 hours ago Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy or progress of CytomX’s or …See details»
CytomX Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CytomX Therapeutics, Inc. of South San Francisco, CA. Get the latest business insights from Dun & …See details»
CytomX lays off 40%, mulls future of Amgen-partnered drug
Jan 7, 2025 CytomX Therapeutics is shrinking its head count by 40% as ... we have taken the difficult decision to streamline our organization and resources towards top priorities and we …See details»
CytomX Therapeutics, Inc.
Corporate and Financial: Organization: In January 2025 , CytomX announced a reduction of organizational headcount by approximately 40 percent in order to direct capital resources …See details»
Governance Overview - CytomX Therapeutics, Inc.
The Investor Relations website contains information about CytomX Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
CytomX Therapeutics - VentureRadar
CytomX has attracted multiple strategic collaborations with industry-leading pharmaceutical companies including Pfizer Inc., ImmunoGen and Bristol-Myers Squibb. CytomX is led by a …See details»
Departments Management Team Archive - CytomX
Danielle Olander-Moghadassian joined CytomX in 2014, and currently serves as consulting chief human resources officer. She is accountable for optimizing talent, bringing organizational …See details»
CytomX Therapeutics Announces Pricing of $100 Million
15 hours ago CytomX’s clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule …See details»
Cytomx LLC Company Profile | South San Francisco, CA
Address: 343 Oyster Point Blvd # 100 South San Francisco, CA, 94080-1913 United StatesSee details»
CytomX Therapeutics Announces First Quarter 2025 Financial …
15 hours ago CytomX Therapeutics Inc. - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients …See details»
Contact - CytomX
CytomX Therapeutics, Inc. 151 Oyster Point Blvd Suite 400 South San Francisco, CA 94080 Offices: 650.515.3185 Fax: 650.351.0353. Investor Relations Contact Chris Ogden Chief …See details»
CytomX Slashes 40% of Workforce, Prioritizes Cancer Drug …
Jan 6, 2025 Organization: In order to direct capital resources to its clinical programs and create additional flexibility in its cost structure, CytomX will reduce organizational headcount by …See details»
CytomX Announces Global Strategic Collaboration with Pfizer to …
Jun 6, 2013 SOUTH SAN FRANCISCO – CytomX Therapeutics, Inc., a biotechnology company developing a new generation of targeted antibody therapeutics, today announced that it has …See details»
Culture & careers - CytomX
CytomX embraces and acknowledges the importance of diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves …See details»
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue …
14 hours ago CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 50% and 43.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to …See details»